消渴丸联合血脂康对2型糖尿病高脂血症MBL的影响

目的:探讨消渴丸联合血脂康对2型糖尿病高脂血症甘露聚糖结合凝集素mannan binding lectin(MBL)的影响.方法:80例2型糖尿病高脂血症患者随机分为观察组和对照组各40例.观察组予以消渴丸,开始10丸/次,早餐及午餐前各1次；血脂康胶囊,2粒/次,口服,2次/d.对照组予以格列本脲片,开始2.5 mg,早餐及午餐前各1次；辛伐他汀,20 mg/次,1次/d.两组均每周根据血糖水平调整消渴丸和格列本脲用量.疗程均为12周.另设健康对照组20例.测量治疗前后空腹血糖(FBG),餐后2h血糖(2 hPG),糖化血红蛋白(HbAlc)及总胆固醇(TC),甘油三酯(TG),低密度脂蛋白胆固醇(LDL-C),高密度脂蛋白(HDL-C),并检测MBL.结果:治疗后两组FBG,2 hPG均较治疗前明显降低,组间比较差异不明显；治疗后两组HbA1c均较治疗前明显降低,观察组HbA1c下降更明显(P＜0.05)；治疗后观察组血脂水平与正常对照组比较差异不明显,对照组LDL-C水平仍高于健康对照组(P＜0.05)；治疗后观察组MBL为(0.71±0.25) mg·L-1,仍低于健康对照组(P＜0.05),但较治疗前明显上升(P＜0.01)；对照组MBL为(0.40 ±0.21)mg·L-1,与治疗前相比呈下降趋势.结论:消渴丸联合血脂康对2型糖尿病高脂血症的血糖及血脂均能有效控制,并能上调MBL水平,有利于炎症的控制.

Effect of Xiaoke Wan and Xuezhikang on Mannan Binding Lectin in Patients with Type2 Diabetes Mellitus and Hyperlipidemia

Objective: To investigate the effect of Xiaoke Wan and Xuezhikang on mannan binding lectin (MBL) in patients with type2 diabetes mellitus and hyperlipidemia. Method: Eighty patients with type2 diabetes mellitus combined with hyperlipidemia were randomly divided into observation group and control group (n=40 each). Observation group was firstly received Xiaoke Wan, 10 pills, before breakfast and lunch. Patients in observation group were also orally received Xuezhikang capsules, 2 capsules, bid. Control group was firstly received glibenclamide tablet, 2.5 mg before breakfast and lunch. Patients in control group were also orally received simvastatin, 20 mg daily. The amount of Xiaoke Wan and glibenclamide were adjusted according to blood glucose level in the two groups. The treatment course of the two groups lasted 12 weeks. Additional 20 normal persons were grouped as the healthy control group. Fasting blood glucose (FBG), level of postprandial 2 h blood glucose (2 hPG), glycated hemoglobin (HbAlc), total cholesterol (TC), triglyceride (TG), low density lipoprotein chotesterol(LDL-C) and high density lipoprotein chotesterol(HDL-C) and MBL were tested before and after treatment. Result: After treatment, FBG and 2 h PBG in the two groups were significantly lower than those before treatment, but there was no significant difference between the two groups. After treatment, HbA1c in the two groups was decreased significantly, and that in observation group decreased more (P<0.05). After treatment, there was no significant difference in blood glucose level between the two groups, LDL-C in control group was still higher than normal control group (P<0.05). After treatment, MBL in observation group was (0.71±0.25) mg·L^-1, which was lower than that in normal control group (P<0.05), but significantly higher than that before treatment (P<0.01). MBL in control group was (0.40±0.21) mg·L^-1, which was lower than that before treatment. Conclusion: Xiaoke Wan combined with Xuezhikang can effectively control blood glucose and lipids in the patients with type2 diabetes mellitus and hyperlipidemia, raise MBL level, and help to control inflammation.